Ocugen Beheer
Beheer criteriumcontroles 2/4
Ocugen's CEO is Shankar Musunuri, appointed in Sep 2013, has a tenure of 11.17 years. total yearly compensation is $4.54M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.65% of the company’s shares, worth $1.78M. The average tenure of the management team and the board of directors is 1.8 years and 4.8 years respectively.
Belangrijke informatie
Shankar Musunuri
Algemeen directeur
US$4.5m
Totale compensatie
Percentage CEO-salaris | 16.7% |
Dienstverband CEO | 11.2yrs |
Eigendom CEO | 0.7% |
Management gemiddelde ambtstermijn | 1.8yrs |
Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$45m |
Mar 31 2024 | n/a | n/a | -US$58m |
Dec 31 2023 | US$5m | US$758k | -US$63m |
Sep 30 2023 | n/a | n/a | -US$82m |
Jun 30 2023 | n/a | n/a | -US$90m |
Mar 31 2023 | n/a | n/a | -US$86m |
Dec 31 2022 | US$8m | US$715k | -US$87m |
Sep 30 2022 | n/a | n/a | -US$74m |
Jun 30 2022 | n/a | n/a | -US$63m |
Mar 31 2022 | n/a | n/a | -US$69m |
Dec 31 2021 | US$8m | US$541k | -US$58m |
Sep 30 2021 | n/a | n/a | -US$48m |
Jun 30 2021 | n/a | n/a | -US$47m |
Mar 31 2021 | n/a | n/a | -US$38m |
Dec 31 2020 | US$2m | US$500k | -US$34m |
Jun 30 2020 | n/a | n/a | -US$30m |
Mar 31 2020 | n/a | n/a | -US$18m |
Dec 31 2019 | US$572k | US$420k | -US$20m |
Sep 30 2019 | n/a | n/a | -US$39m |
Jun 30 2019 | n/a | n/a | -US$18m |
Mar 31 2019 | n/a | n/a | -US$19m |
Dec 31 2018 | US$431k | US$420k | -US$18m |
Compensatie versus markt: Shankar's total compensation ($USD4.54M) is above average for companies of similar size in the US market ($USD1.48M).
Compensatie versus inkomsten: Shankar's compensation has been consistent with company performance over the past year.
CEO
Shankar Musunuri (60 yo)
11.2yrs
Tenure
US$4,535,231
Compensatie
Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. since September 2013 and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Pr...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 11.2yrs | US$4.54m | 0.65% $ 1.8m | |
Co-founder & Independent Director | 11.2yrs | US$102.13k | 0.24% $ 669.3k | |
Chief Scientific Officer and Head of Research & Development | 2.2yrs | US$1.38m | 0.038% $ 103.6k | |
Chief Accounting Officer | less than a year | geen gegevens | geen gegevens | |
General Counsel | no data | geen gegevens | geen gegevens | |
AVP & Head of Corporate Communications | no data | geen gegevens | geen gegevens | |
Head of People & Culture | less than a year | geen gegevens | geen gegevens | |
Senior Vice President of Commercial | 3.4yrs | geen gegevens | geen gegevens | |
VP & Head of Regulatory & Quality | 1.8yrs | geen gegevens | geen gegevens | |
Chief Medical Officer | less than a year | geen gegevens | 0.00057% $ 1.6k | |
VP, Head of Program Management & Chief of Staff | less than a year | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: OCGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 5.2yrs | US$4.54m | 0.65% $ 1.8m | |
Co-founder & Independent Director | 5.2yrs | US$102.13k | 0.24% $ 669.3k | |
Lead Independent Director | 4.6yrs | US$124.63k | 0% $ 0 | |
Independent Director | 2.7yrs | US$103.32k | 0.00035% $ 956.4 | |
Member of Retina Scientific Advisory Board | 5yrs | geen gegevens | geen gegevens | |
Member of Retina Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Vaccine Scientific Advisory Board Member | 3.9yrs | geen gegevens | geen gegevens | |
Independent Director | 5.2yrs | US$87.13k | 0.40% $ 1.1m | |
Member of Retina Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Director | 4.6yrs | US$110.82k | 0.017% $ 47.5k | |
Vaccine Scientific Advisory Board Member | 3.9yrs | geen gegevens | geen gegevens | |
Member of Retina Scientific Advisory Board | 5yrs | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: OCGN's board of directors are considered experienced (4.8 years average tenure).